Biotech entity
pharma is the sole category represented across all 1 tracked stories. Zasturi is most often covered alongside Cerus Corporation, which appears in 1 of these 1 story. The tracked stories average 11 original sources each. Zasturi appears in 1 tracked Biotech story from March 3, 2026.
Last mentioned: Mar 3, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Zasturi is most often covered alongside Cerus Corporation, which appears in 1 of these 1 story. The tracked stories average 11 original sources each. Zasturi appears in 1 tracked Biotech story from March 3, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Zasturi. Shared-story counts are live from our verified record — not editorial picks.
UroGen Pharma and Senseonics reported strong Q4 2025 results, driven by the successful commercial launches of Zasturi and Eversense 365. Both companies are navigating critical transitions—UroGen through new reimbursement codes and Senseonics by assuming full commercial control—positioning them for significant revenue scaling in 2026.
Zasturi is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
